SCHEMBL20204992

SCHEMBL20204992

N#Cc1ccc2c(c1)=CC(=O)N=2

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA2 P00918 3/20 0.40
CA1 P00915 2/20 0.40
NOS3 P29474 1/20 0.34
NOS1 P29475 1/20 0.34
NOS2 P35228 1/20 0.34
CASP3 P42574 1/20 0.33
VCAM1 P19320 1/20 0.32
ALDH1A1 P00352 2/20 0.31
PIN1 Q13526 1/20 0.31
KDM4E B2RXH2 1/20 0.31
GLA P06280 1/20 0.31
GAA P10253 1/20 0.31
CYP2A6 P11509 2/20 0.31
IMPDH2 P12268 1/20 0.31
IMPDH1 P20839 1/20 0.31
TRPV4 Q9HBA0 1/20 0.30
TNKS O95271 1/20 0.30
CA12 O43570 1/20 0.30
CA3 P07451 1/20 0.30
CA6 P23280 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1435831 0.78 ALDH1A1 (0.39) CA2CA1ALDH1A1KDM4EGAA
SCHEMBL29111860 0.64 TAAR1 (0.39) ALDH1A1KDM4EGAACYP2A6
SCHEMBL19926284 0.63 CYP2A6 (0.37) CA2CA1NOS3NOS1NOS2
Methane SCHEMBL28737048 0.63 MEN1 (0.36) ALDH1A1KDM4E
SCHEMBL29921145 0.63 MEN1 (0.36) ALDH1A1KDM4E
Charcoal, Activated SCHEMBL29882480 0.63 MEN1 (0.36) ALDH1A1KDM4E
SCHEMBL28363865 0.63 MEN1 (0.36) ALDH1A1KDM4E
SCHEMBL16713592 0.62 CASP3 (0.46) CA2CA1NOS3NOS1NOS2
SCHEMBL2104832 0.61 CYP2A6 (0.33) CA2CA1VCAM1CYP2A6
SCHEMBL28367503 0.60 MEN1 (0.35) ALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11789025-B2 Reagents and methods for analysis of proteins and metabolites targeted by covalent probes DANA-FARBER CANCER INSTITUTE, INC. (US) 2023-10-17 US disclosed
US-11789025-B2 Reagents and methods for analysis of proteins and metabolites targeted by covalent probes DANA-FARBER CANCER INSTITUTE, INC. (US) 2023-10-17 US disclosed
US-10969394-B2 Reagents and methods for analysis of proteins and metabolites targeted by covalent probes DANA-FARBER CANCER INSTITUTE, INC. (US) 2021-04-06 US disclosed
US-20210072254-A1 Reagents and Methods for Analysis of Proteins and Metabolites Targeted by Covalent Probes DANA-FARBER CANCER INSTITUTE, INC. 2021-03-11 US disclosed
US-20190346454-A1 Reagents and Methods for Analysis of Proteins and Metabolites Targeted by Covalent Probes DANA-FARBER CANCER INSTITUTE, INC. 2019-11-14 US disclosed
WO-2018098473-A1 REAGENTS AND METHODS FOR ANALYSIS OF PROTEINS AND METABOLITES TARGETED BY COVALENT PROBES DANA-FARBER CANCER INSTITUTE, INC. (US) 2018-05-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10969394-B2 Reagents and methods for analysis of proteins and metabolites targeted by covalent probes PTMS, SRMS, HSP90B1 CA2 2807/4885CA1 1657/4885NOS3 3567/4885
US-11789025-B2 Reagents and methods for analysis of proteins and metabolites targeted by covalent probes PTMS, SRMS, HSP90B1 CA2 2807/4885CA1 1657/4885NOS3 3567/4885
US-20210072254-A1 Reagents and Methods for Analysis of Proteins and Metabolites Targeted by Covalent Probes PTMS, SRMS, HSP90B1 CA2 2807/4885CA1 1657/4885NOS3 3567/4885
US-20190346454-A1 Reagents and Methods for Analysis of Proteins and Metabolites Targeted by Covalent Probes PTMS, SRMS, HSP90B1 CA2 2807/4885CA1 1657/4885NOS3 3567/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.